Spots Global Cancer Trial Database for A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer
Official Title: An Open Label Phase 1 Study of SC-006 as a Single Agent and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer
Study ID: NCT03035279
Conditions
Study Description
Brief Summary: This is a multicenter, open-label, Phase 1 study of SC-006 given as a single agent and in combination with ABBV-181 in participants with advanced colorectal cancer (CRC), and consists of Part A (single agent SC-006 dose regimen finding), followed by Part B (single agent SC-006 dose expansion), and Part C (SC-006 and ABBV-181 combination escalation and expansion). Part A (dose regimen finding) will involve dose escalation and possible dose interval modification to define the maximum tolerated dose (MTD) and/or recommended Part B dose and schedule. Part B (dose expansion) will enroll additional participants who will be treated with a study drug dose at or below the MTD determined in Part A. Part C is dose escalation of SC-006 and fixed dose of ABBV-181 in combination. Recommended dose cohort of SC-006 with ABBV-181 will be expanded.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Highlands Oncology Group /ID# 201182, Fayetteville, Arkansas, United States
University of California, Los Angeles /ID# 160882, Los Angeles, California, United States
University of Michigan Hospitals /ID# 167101, Ann Arbor, Michigan, United States
Mayo Clinic - Rochester /ID# 160884, Rochester, Minnesota, United States
Washington University-School of Medicine /ID# 160883, Saint Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center /ID# 160881, New York, New York, United States
Carolina BioOncology Institute /ID# 202712, Huntersville, North Carolina, United States
Oklahoma University /ID# 202713, Oklahoma City, Oklahoma, United States
Tennessee Oncology-Nashville Centennial /ID# 160880, Nashville, Tennessee, United States
Contact Details
Name: AbbVie Inc.
Affiliation: AbbVie
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
